vs
Orion Group Holdings Inc（ORN）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
Orion Group Holdings Inc的季度营收约是REPLIGEN CORP的1.1倍（$216.3M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs 2.2%，领先4.5%），Orion Group Holdings Inc同比增速更快（14.6% vs 13.6%），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 6.1%）
奥里昂集团是源自芬兰的全球化制药企业，1917年成立，总部位于芬兰埃斯波。公司面向全球市场研发、生产并销售人用与兽用药品以及药用活性成分，旗下全部生产基地与大部分研发部门均设立在芬兰。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
ORN vs RGEN — 直观对比
营收规模更大
ORN
是对方的1.1倍
$197.9M
营收增速更快
ORN
高出1.0%
13.6%
净利率更高
RGEN
高出4.5%
2.2%
两年增速更快
RGEN
近两年复合增速
6.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $216.3M | $197.9M |
| 净利润 | $4.7M | $13.3M |
| 毛利率 | 12.0% | 52.5% |
| 营业利润率 | — | 9.0% |
| 净利率 | 2.2% | 6.7% |
| 营收同比 | 14.6% | 13.6% |
| 净利润同比 | 435.7% | 143.9% |
| 每股收益（稀释后） | $0.12 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ORNRGEN
| Q1 26 | $216.3M | — | ||
| Q4 25 | $233.2M | $197.9M | ||
| Q3 25 | $225.1M | $188.8M | ||
| Q2 25 | $205.3M | $182.4M | ||
| Q1 25 | $188.7M | $169.2M | ||
| Q4 24 | $216.9M | $174.1M | ||
| Q3 24 | $226.7M | $154.9M | ||
| Q2 24 | $192.2M | $154.1M |
净利润ORNRGEN
| Q1 26 | $4.7M | — | ||
| Q4 25 | $-240.0K | $13.3M | ||
| Q3 25 | $3.3M | $14.9M | ||
| Q2 25 | $841.0K | $14.9M | ||
| Q1 25 | $-1.4M | $5.8M | ||
| Q4 24 | $6.8M | $-30.3M | ||
| Q3 24 | $4.3M | $-654.0K | ||
| Q2 24 | $-6.6M | $3.3M |
毛利率ORNRGEN
| Q1 26 | 12.0% | — | ||
| Q4 25 | 11.6% | 52.5% | ||
| Q3 25 | 13.2% | 53.2% | ||
| Q2 25 | 12.6% | 50.0% | ||
| Q1 25 | 12.2% | 53.6% | ||
| Q4 24 | 14.0% | 26.1% | ||
| Q3 24 | 11.9% | 50.0% | ||
| Q2 24 | 9.5% | 49.8% |
营业利润率ORNRGEN
| Q1 26 | — | — | ||
| Q4 25 | 2.2% | 9.0% | ||
| Q3 25 | 2.4% | 8.9% | ||
| Q2 25 | 1.7% | 7.6% | ||
| Q1 25 | 0.4% | 3.9% | ||
| Q4 24 | 4.4% | -17.7% | ||
| Q3 24 | 3.4% | -5.1% | ||
| Q2 24 | -1.4% | 1.0% |
净利率ORNRGEN
| Q1 26 | 2.2% | — | ||
| Q4 25 | -0.1% | 6.7% | ||
| Q3 25 | 1.5% | 7.9% | ||
| Q2 25 | 0.4% | 8.2% | ||
| Q1 25 | -0.7% | 3.4% | ||
| Q4 24 | 3.1% | -17.4% | ||
| Q3 24 | 1.9% | -0.4% | ||
| Q2 24 | -3.4% | 2.2% |
每股收益（稀释后）ORNRGEN
| Q1 26 | $0.12 | — | ||
| Q4 25 | $-0.00 | $0.24 | ||
| Q3 25 | $0.08 | $0.26 | ||
| Q2 25 | $0.02 | $0.26 | ||
| Q1 25 | $-0.04 | $0.10 | ||
| Q4 24 | $0.22 | $-0.55 | ||
| Q3 24 | $0.12 | $-0.01 | ||
| Q2 24 | $-0.20 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.3M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $166.7M | $2.1B |
| 总资产 | $478.7M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资ORNRGEN
| Q1 26 | $6.3M | — | ||
| Q4 25 | $1.6M | $767.6M | ||
| Q3 25 | $4.9M | $748.7M | ||
| Q2 25 | $1.7M | $708.9M | ||
| Q1 25 | $13.0M | $697.2M | ||
| Q4 24 | $28.3M | $757.4M | ||
| Q3 24 | $28.3M | $784.0M | ||
| Q2 24 | $4.8M | $809.1M |
总债务ORNRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $23.3M | — | ||
| Q4 24 | $23.2M | $525.6M | ||
| Q3 24 | $28.0M | — | ||
| Q2 24 | $60.3M | — |
股东权益ORNRGEN
| Q1 26 | $166.7M | — | ||
| Q4 25 | $159.0M | $2.1B | ||
| Q3 25 | $157.9M | $2.1B | ||
| Q2 25 | $153.2M | $2.1B | ||
| Q1 25 | $150.8M | $2.0B | ||
| Q4 24 | $150.7M | $2.0B | ||
| Q3 24 | $142.4M | $2.0B | ||
| Q2 24 | $111.1M | $2.0B |
总资产ORNRGEN
| Q1 26 | $478.7M | — | ||
| Q4 25 | $414.7M | $2.9B | ||
| Q3 25 | $422.4M | $2.9B | ||
| Q2 25 | $432.7M | $2.9B | ||
| Q1 25 | $416.3M | $2.9B | ||
| Q4 24 | $417.3M | $2.8B | ||
| Q3 24 | $430.3M | $2.8B | ||
| Q2 24 | $414.0M | $2.9B |
负债/权益比ORNRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | 0.27× | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流ORNRGEN
| Q1 26 | — | — | ||
| Q4 25 | $13.8M | $25.7M | ||
| Q3 25 | $23.3M | $48.1M | ||
| Q2 25 | $-5.6M | $28.6M | ||
| Q1 25 | $-3.4M | $15.0M | ||
| Q4 24 | $13.4M | $39.2M | ||
| Q3 24 | $37.5M | $49.3M | ||
| Q2 24 | $-15.3M | $42.2M |
自由现金流ORNRGEN
| Q1 26 | — | — | ||
| Q4 25 | $454.0K | $17.6M | ||
| Q3 25 | $13.9M | $43.4M | ||
| Q2 25 | $-12.7M | $21.5M | ||
| Q1 25 | $-12.5M | $11.4M | ||
| Q4 24 | $9.9M | $33.6M | ||
| Q3 24 | $33.3M | $42.3M | ||
| Q2 24 | $-20.0M | $37.4M |
自由现金流率ORNRGEN
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 8.9% | ||
| Q3 25 | 6.2% | 23.0% | ||
| Q2 25 | -6.2% | 11.8% | ||
| Q1 25 | -6.6% | 6.8% | ||
| Q4 24 | 4.6% | 19.3% | ||
| Q3 24 | 14.7% | 27.3% | ||
| Q2 24 | -10.4% | 24.3% |
资本支出强度ORNRGEN
| Q1 26 | — | — | ||
| Q4 25 | 5.7% | 4.1% | ||
| Q3 25 | 4.2% | 2.5% | ||
| Q2 25 | 3.5% | 3.9% | ||
| Q1 25 | 4.8% | 2.1% | ||
| Q4 24 | 1.6% | 3.2% | ||
| Q3 24 | 1.8% | 4.5% | ||
| Q2 24 | 2.4% | 3.1% |
现金转化率ORNRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 1.93× | ||
| Q3 25 | 7.05× | 3.23× | ||
| Q2 25 | -6.61× | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | 1.98× | — | ||
| Q3 24 | 8.79× | — | ||
| Q2 24 | — | 12.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
